|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/10/23 Chemours Co. 10-K 12/31/22 185:39M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 9.33M
2: EX-21 Subsidiaries List HTML 81K
3: EX-22 Published Report re: Matters Submitted to a Vote HTML 51K
of Security Holders
4: EX-23 Consent of Expert or Counsel HTML 49K
9: EX-95 Mine-Safety Disclosure HTML 62K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 54K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 54K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 50K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 50K
15: R1 Document and Entity Information HTML 119K
16: R2 Consolidated Statements of Operations HTML 132K
17: R3 Consolidated Statements of Comprehensive Income HTML 162K
18: R4 Consolidated Balance Sheets HTML 186K
19: R5 Consolidated Balance Sheets (Parenthetical) HTML 60K
20: R6 Consolidated Statements of Stockholders' Equity HTML 114K
21: R7 Consolidated Statements of Stockholders' Equity HTML 51K
(Parenthetical)
22: R8 Consolidated Statements of Cash Flows HTML 174K
23: R9 Background and Description of the Business HTML 62K
24: R10 Basis of Presentation HTML 53K
25: R11 Summary of Significant Accounting Policies HTML 153K
26: R12 Acquisitions and Divestitures HTML 59K
27: R13 Net Sales HTML 316K
28: R14 Research and Development Expense HTML 93K
29: R15 Restructuring, Asset-Related, and Other Charges HTML 311K
30: R16 Other Income (Expense), Net HTML 100K
31: R17 Income Taxes HTML 517K
32: R18 Earnings Per Share of Common Stock HTML 120K
33: R19 Accounts and Notes Receivable, Net HTML 111K
34: R20 Inventories HTML 87K
35: R21 Property, Plant, and Equipment, Net HTML 97K
36: R22 Leases HTML 335K
37: R23 Goodwill and Other Intangible Assets, Net HTML 200K
38: R24 Investments in Affiliates HTML 132K
39: R25 Other Assets HTML 77K
40: R26 Accounts Payable HTML 69K
41: R27 Other Accrued Liabilities HTML 90K
42: R28 Debt HTML 350K
43: R29 Other Liabilities HTML 81K
44: R30 Commitments and Contingent Liabilities HTML 484K
45: R31 Equity HTML 114K
46: R32 Stock-based Compensation HTML 365K
47: R33 Accumulated Other Comprehensive Loss HTML 132K
48: R34 Financial Instruments HTML 269K
49: R35 Long-term Employee Benefits HTML 567K
50: R36 Supplemental Cash Flow Information HTML 71K
51: R37 Geographic and Segment Information HTML 536K
52: R38 Summary of Significant Accounting Policies HTML 208K
(Policies)
53: R39 Net Sales (Tables) HTML 303K
54: R40 Research and Development Expense (Tables) HTML 91K
55: R41 Restructuring, Asset-Related, and Other Charges HTML 286K
(Tables)
56: R42 Other Income (Expense), Net (Tables) HTML 99K
57: R43 Income Taxes (Tables) HTML 511K
58: R44 Earnings Per Share of Common Stock (Tables) HTML 121K
59: R45 Accounts and Notes Receivable, Net (Tables) HTML 110K
60: R46 Inventories (Tables) HTML 82K
61: R47 Property, Plant, and Equipment, Net (Tables) HTML 89K
62: R48 Leases (Tables) HTML 334K
63: R49 Goodwill and Other Intangible Assets, Net (Tables) HTML 193K
64: R50 Investments in Affiliates (Tables) HTML 127K
65: R51 Other Assets (Tables) HTML 76K
66: R52 Accounts Payable (Tables) HTML 69K
67: R53 Other Accrued Liabilities (Tables) HTML 89K
68: R54 Debt (Tables) HTML 235K
69: R55 Other Liabilities (Tables) HTML 80K
70: R56 Commitments and Contingent Liabilities (Tables) HTML 265K
71: R57 Equity (Tables) HTML 94K
72: R58 Stock-based Compensation (Tables) HTML 327K
73: R59 Accumulated Other Comprehensive Loss (Tables) HTML 131K
74: R60 Financial Instruments (Tables) HTML 234K
75: R61 Long-term Employee Benefits (Tables) HTML 551K
76: R62 Supplemental Cash Flow Information (Tables) HTML 69K
77: R63 Geographic and Segment Information (Tables) HTML 528K
78: R64 Background and Description of the Business - HTML 61K
Narrative (Details)
79: R65 Summary of Significant Accounting Policies - HTML 106K
Narrative (Details)
80: R66 Acquisitions and Divestitures - Narrative HTML 75K
(Details)
81: R67 Net Sales - Summary of Disaggregation of Net Sales HTML 118K
by Geographical Region and Segment and Product
Group (Details)
82: R68 Net Sales - Summary of Contract Balances from HTML 57K
Contracts with Customers (Details)
83: R69 Net Sales - Narrative (Details) HTML 54K
84: R70 Net Sales - Narrative (Details1) HTML 57K
85: R71 Research and Development Expense - Summary of R&D HTML 63K
Expense by Segment (Details)
86: R72 Restructuring, Asset-Related, and Other Charges - HTML 59K
Schedule of Restructuring Program (Details)
87: R73 Restructuring, Asset-Related, and Other Charges - HTML 92K
Schedule of Restructuring Programs to Segment
(Details)
88: R74 Restructuring, Asset-Related, and Other Charges - HTML 130K
Narrative (Details)
89: R75 Restructuring, Asset-Related, and Other Charges - HTML 62K
Restructuring Program Schedule (Details)
90: R76 Other Income (Expense), Net - Components of Other HTML 60K
Income (Expense) (Details)
91: R77 Other Income (Expense), Net - Components of Other HTML 63K
Income (Expense) (Parenthetical) (Details)
92: R78 Income Taxes - Schedule of Components of Provision HTML 78K
for (Benefit from) Income Taxes (Details)
93: R79 Income Taxes - Components of Deferred Tax Assets HTML 80K
and Liabilities (Details)
94: R80 Income Taxes - Effective Income Tax Rate HTML 81K
Reconciliation (Details)
95: R81 Income Taxes - Effective Income Tax Reconciliation HTML 81K
(Details)
96: R82 Income Taxes - Summary of Income (Loss) Before HTML 59K
Income Taxes (Details)
97: R83 Income Taxes - Narrative (Details) HTML 96K
98: R84 Income Taxes - Summary of open tax years by HTML 77K
significant jurisdiction (Details)
99: R85 Income Taxes - Unrecognized Tax Benefits (Details) HTML 68K
100: R86 Income Taxes - Summary of Valuation Allowance HTML 57K
(Details)
101: R87 Earnings Per Share of Common Stock - Schedule of HTML 83K
Earnings Per Share, Basic and Diluted (Details)
102: R88 Earnings Per Share of Common Stock - Schedule of HTML 51K
Anti-dilutive Securities Excluded from Computation
of Earnings Per Share (Details)
103: R89 Accounts and Notes Receivable, Net - Schedule of HTML 57K
Accounts and Notes Receivable (Details)
104: R90 Accounts and Notes Receivable, Net - Schedule of HTML 56K
Accounts and Notes Receivable (Parenthetical)
(Details)
105: R91 Accounts and Notes Receivable, Net - (Narrative) HTML 51K
(Details)
106: R92 Accounts and Notes Receivable, Net - Schedule of HTML 56K
Allowance for Doubtful Accounts (Details)
107: R93 Accounts and Notes Receivable, Net - Schedule of HTML 53K
Allowance for Doubtful Accounts (Parenthetical)
(Details)
108: R94 Inventories - Schedule of Inventories (Details) HTML 61K
109: R95 Inventories - Narrative (Details) HTML 65K
110: R96 Property, Plant, and Equipment, Net - Summary of HTML 68K
Property, Plant, and Equipment, Net (Details)
111: R97 Property, Plant, and Equipment, Net - Narrative HTML 55K
(Details)
112: R98 Leases - Narrative (Details) HTML 54K
113: R99 Leases - Schedule of Lease Assets and Lease HTML 80K
Liabilities and their Balance Sheet Locations
(Details)
114: R100 Leases - Schedule of Components of Company's Lease HTML 63K
Cost (Details)
115: R101 Leases - Schedule of Cash Flows Related to HTML 63K
Company's Leases (Details)
116: R102 Leases - Schedule of Weighted-Average Terms and HTML 60K
Weighted-Average Discount Rates For Company's
Leases (Details)
117: R103 Leases - Schedule of Company's Lease Liabilities' HTML 107K
Maturities For Next Five Years and Thereafter
(Details)
118: R104 Leases - Build-to-suit Lease Obligation - HTML 56K
Narrative (Details)
119: R105 Leases - Summary of Future Minimum Lease Payments HTML 62K
Related to Chemours Discovery Hub Financing
Obligation (Detail)
120: R106 Goodwill and Other Intangible Assets, Net - HTML 66K
Schedule of Goodwill (Details)
121: R107 Goodwill and Other Intangible Assets, Net - HTML 88K
Narrative (Details)
122: R108 Goodwill and Other Intangible Assets, Net - HTML 75K
Schedule of Other Intangible Assets (Details)
123: R109 Investments in Affiliates - Narrative (Details) HTML 62K
124: R110 Investments in Affiliates - Schedule of HTML 65K
Investments in Affiliates (Details)
125: R111 Investments in Affiliates - Schedule of Changes in HTML 60K
Investments in Affiliates (Details)
126: R112 Other Assets - Schedule of Other Assets (Details) HTML 60K
127: R113 Accounts Payable - Schedule of Accounts Payable HTML 56K
(Details)
128: R114 Other Accrued Liabilities - Schedule of Other HTML 67K
Accrued Liabilities (Details)
129: R115 Debt - Components of Debt (Details) HTML 83K
130: R116 Debt - Components of Debt (Parenthetical) HTML 74K
(Details)
131: R117 Debt - Senior Secured Credit Facilities - HTML 132K
Narrative (Details)
132: R118 Debt - Senior Unsecured Notes - Narrative HTML 208K
(Details)
133: R119 Debt - Note Repurchases - Narrative (Details) HTML 59K
134: R120 Debt - Accounts Receivable Securitization Facility HTML 78K
- Narrative (Details)
135: R121 Debt - Other - Narrative (Details) HTML 54K
136: R122 Debt - Maturities and Fair Value - Narrative HTML 63K
(Details)
137: R123 Debt - Schedule of Debt Principal Maturities HTML 70K
(Details)
138: R124 Debt - Estimated Fair Values of Senior Debt Issues HTML 95K
(Details)
139: R125 Debt - Estimated Fair Values of Senior Debt Issues HTML 72K
(Parenthetical) (Details)
140: R126 Other Liabilities - Schedule of Other Liabilities HTML 60K
(Details)
141: R127 Other Liabilities - Schedule of Other Liabilities HTML 50K
(Parenthetical) (Details)
142: R128 Commitments and Contingent Liabilities - Summary HTML 66K
of Asset Retirement Obligations (Details)
143: R129 Commitments and Contingent Liabilities - Schedule HTML 61K
of Components of Accrued Litigation (Details)
144: R130 Commitments and Contingent Liabilities - Schedule HTML 58K
of Components of Accrued Litigation
(Parenthetical) (Details)
145: R131 Commitments and Contingent Liabilities - Schedule HTML 62K
of Current and Long-term Components of Accrued
Litigation and Balance Sheet Locations (Details)
146: R132 Commitments and Contingent Liabilities - Schedule HTML 56K
of Current and Long-term Components of Accrued
Litigation and Balance Sheet Locations
(Parenthetical) (Details)
147: R133 Commitments and Contingent Liabilities - HTML 242K
Litigation - Narrative (Details)
148: R134 Commitments and Contingent Liabilities - Schedule HTML 74K
of Environmental Remediation Liabilities (Details)
149: R135 Commitments and Contingent Liabilities - Schedule HTML 55K
of Environmental Remediation Liabilities
(Parenthetical) (Details)
150: R136 Commitments and Contingent Liabilities - Schedule HTML 59K
of Current and Long-term Components of
Environmental Remediation Liabilities (Details)
151: R137 Commitments and Contingent Liabilities - HTML 153K
Environmental - Narrative (Details)
152: R138 Commitments and Contingent - Schedule of HTML 60K
Components of Accrued Environmental Remediation
Liabilities Related to PFAS (Details)
153: R139 Commitments and Contingent Liabilities - Schedule HTML 63K
of Current and Long-term Components of Accrued
Environmental Remediation Liabilities (Details)
154: R140 Equity - Narrative (Details) HTML 82K
155: R141 Equity - Schedule of Share Repurchase Activity HTML 63K
(Details)
156: R142 Stock-based Compensation - Narrative (Details) HTML 133K
157: R143 Stock-based Compensation - Weighted Average HTML 62K
Assumptions of Stock Option (Details)
158: R144 Stock-based Compensation - Stock Option Activity HTML 96K
(Details)
159: R145 Stock-based Compensation - Restricted Stock Units HTML 74K
Activity (Details)
160: R146 Stock-based Compensation - Performance Share Units HTML 74K
Activity (Details)
161: R147 Accumulated Other Comprehensive Loss - Schedule of HTML 71K
Accumulated Other Comprehensive Loss (Details)
162: R148 Financial Instruments - Narrative (Details) HTML 113K
163: R149 Financial Instruments - Schedule of Derivative HTML 69K
Assets and Liabilities At Fair Value (Details)
164: R150 Financial Instruments - Schedule of Pre-tax Charge HTML 75K
Fair Value of Financial Instruments (Details)
165: R151 Long-term Employee Benefits (Narrative) (Details) HTML 77K
166: R152 Long-term Employee Benefits (Schedule of Net HTML 106K
Periodic Pension (Cost) Income and Amounts
Recognized in Other Comprehensive Income (Loss)
(Details)
167: R153 Long-term Employee Benefits (Amounts Recognized in HTML 60K
Accumulated Other Comprehensive Loss) (Details)
168: R154 Long-term Employee Benefits (Change in Benefit HTML 99K
Obligation and Plan Assets) (Details)
169: R155 Long-term Employee Benefits (Amounts Recognized in HTML 67K
Balance Sheet) (Details)
170: R156 Long-term Employee Benefits (Summary of Projected HTML 69K
Benefit Obligations and Accumulated Benefit
Obligations in Excess of Plan Assets) (Details)
171: R157 Long-term Employee Benefits (Assumptions) HTML 65K
(Details)
172: R158 Long-term Employee Benefits (Plan Assets) HTML 102K
(Details)
173: R159 Long-term Employee Benefits (Cash Flows Defined HTML 72K
Benefit Plans) (Details)
174: R160 Supplemental Cash Flow information - HTML 60K
Reconciliation of Cash, Cash Equivalents,
Restricted Cash and Restricted Cash Equivalents
(Details)
175: R161 Geographic and Segment Information - Schedule of HTML 68K
Net Sales and Property, Plant and Equipment, Net
by Geographical Area (Details)
176: R162 Geographic and Segment Information - Narrative HTML 51K
(Details)
177: R163 Geographic and Segment Information - Schedule of HTML 99K
Segment Information (Details)
178: R164 Geographic and Segment Information - Summary of HTML 69K
Reconciliation for Summary Financial Information
for Reportable Segments (Details)
179: R165 Geographic and Segment Information - HTML 80K
Reconciliation of Segment Adjusted EBITDA from
Segments to Consolidated Income (Loss) Before
Income Taxes (Details)
180: R166 Geographic and Segment Information - HTML 62K
Reconciliation of Segment Adjusted EBITDA from
Segments to Consolidated Income (Loss) Before
Income Taxes (Details) (Parenthetical) (Details)
183: XML IDEA XML File -- Filing Summary XML 365K
181: XML XBRL Instance -- cc-20221231_htm XML 11.43M
182: EXCEL IDEA Workbook of Financial Reports XLSX 393K
10: EX-101.CAL XBRL Calculations -- cc-20221231_cal XML 492K
11: EX-101.DEF XBRL Definitions -- cc-20221231_def XML 2.00M
13: EX-101.LAB XBRL Labels -- cc-20221231_lab XML 3.49M
12: EX-101.PRE XBRL Presentations -- cc-20221231_pre XML 2.95M
14: EX-101.SCH XBRL Schema -- cc-20221231 XSD 545K
184: JSON XBRL Instance as JSON Data -- MetaLinks 1,018± 1.73M
185: ZIP XBRL Zipped Folder -- 0000950170-23-002467-xbrl Zip 1.21M
| EX-31.1 |
Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
I, Mark E. Newman, certify that:
1. I have reviewed this Annual Report on Form 10-K of The Chemours Company;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and,
d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and,
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and,
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: |
|
|
|
|
|
By: |
|
/s/ Mark E. Newman |
|
|
|
|
|
|
|
|
President and Chief Executive Officer |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/10/23 | None on these Dates | ||
| For Period end: | 12/31/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/10/24 SEC UPLOAD¶ 2/08/24 2:39K Chemours Co. 1/03/24 SEC UPLOAD¶ 2/08/24 2:42K Chemours Co. 12/13/23 SEC UPLOAD¶ 2/08/24 2:49K Chemours Co. |